These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37657262)

  • 21. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
    Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
    Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Economic impact of ferric carboxymaltose in haemodialysis patients].
    Aiello A; Berto P; Conti P; Panichi V; Rosati A
    G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hypophosphatemia after injectable iron treatments in adults: Comparison between ferric carboxymaltose and iron sucrose].
    Grino M; Rigaux M; Lagarde AV; Robert V; Papailhau C; Vincentelli MB
    Ann Pharm Fr; 2023 Sep; 81(5):790-800. PubMed ID: 36963655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
    Neiser S; Koskenkorva TS; Schwarz K; Wilhelm M; Burckhardt S
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.
    Koskenkorva-Frank TS; Weiss G; Koppenol WH; Burckhardt S
    Free Radic Biol Med; 2013 Dec; 65():1174-1194. PubMed ID: 24036104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
    Pollock RF; Muduma G
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
    Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
    Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
    Funk F; Flühmann B; Barton AE
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes.
    Burgert M; Marques CB; Borchard G; Philipp E; Wilhelm M; Alston A; Digigow R
    J Vis Exp; 2023 Jul; (197):. PubMed ID: 37486118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of different intravenous iron preparations in terms of total oxidant and total antioxidant status, single center data.
    Can F; Yılmaz KN; Kösemehmetoglu OS; Akıncı S; Güney T
    Ann Hematol; 2023 Oct; 102(10):2645-2650. PubMed ID: 37432415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of transition from intravenous iron sucrose to ferric carboxymaltose infusions in pediatric patients with intestinal failure.
    Kaenkumchorn TK; Rosete BE; Carlin K; Fukasawa S; Horslen SP; Wendel D
    JPEN J Parenter Enteral Nutr; 2022 Sep; 46(7):1578-1584. PubMed ID: 35616288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.